Sheba Medical Center and Swiss-based Lonza Pharma collaborate to enhance patient access to CAR T-cell immunotherapy
Sheba Medical Center and Swiss-based CDMO Lonza Pharma recently announced a new collaborative venture to use the cutting-edge CocoonTM manufacturing platform to develop point-of-care CAR T-cell therapy. This joint project aims to streamline the in-house cell manufacturing process, thereby enabling a greater amount of critically ill oncology patients to access genetically engineered human CAR T-cells more efficiently.